StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3059% below fair value
$0.41−0.07 (-14.34%)

Close on Nov 18, 2026Market cap $63.33MP/E –Yield –

Coherus Oncology operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Coherus Oncology's operating income for the twelve months ending Jun 30, 2026 was -$158.70M. For fiscal 2025 it was -$181.13M. The highest annual figure on record is $156.32M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$181.13M–
FY2024Dec 31, 2024-$199.65M–
FY2023Dec 31, 2023-$203.20M–
FY2022Dec 31, 2022-$256.88M–
FY2021Dec 31, 2021-$263.86M-268.8%
FY2020Dec 31, 2020$156.32M+45.1%
FY2019Dec 31, 2019$107.77M–
FY2018Dec 31, 2018-$204.42M–
FY2017Dec 31, 2017-$232.14M–
FY2016Dec 31, 2016-$115.93M–
FY2015Dec 31, 2015-$219.07M–
FY2014Dec 31, 2014-$64.68M–
FY2013Dec 31, 2013-$35.99M–
FY2012Dec 31, 2012-$38.52M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$32.33M–
Q1 FY2026Mar 31, 2026-$36.15M–
Q4 FY2025Dec 31, 2025-$45.88M–
Q3 FY2025Sep 30, 2025-$44.33M–
Q2 FY2025Jun 30, 2025-$45.49M–
Q1 FY2025Mar 31, 2025-$45.44M–
Q4 FY2024Dec 31, 2024-$45.38M–
Q3 FY2024Sep 30, 2024-$46.86M–
Q2 FY2024Jun 30, 2024-$39.63M–
Q1 FY2024Mar 31, 2024-$67.79M–
Q4 FY2023Dec 31, 2023-$68.91M–
Q3 FY2023Sep 30, 2023-$32.01M–
Q2 FY2023Jun 30, 2023-$34.54M–
Q1 FY2023Mar 31, 2023-$67.75M–
Q4 FY2022Dec 31, 2022-$51.49M–
Q3 FY2022Sep 30, 2022-$80.45M–
Q2 FY2022Jun 30, 2022-$44.01M–
Q1 FY2022Mar 31, 2022-$80.93M–
Q4 FY2021Dec 31, 2021-$39.55M-340.8%
Q3 FY2021Sep 30, 2021-$32.79M-197.2%
Q2 FY2021Jun 30, 2021-$24.16M-137.0%
Q1 FY2021Mar 31, 2021-$167.36M-509.5%
Q4 FY2020Dec 31, 2020$16.43M-63.5%
Q3 FY2020Sep 30, 2020$33.72M-35.0%
Q2 FY2020Jun 30, 2020$65.31M+137.6%
Q1 FY2020Mar 31, 2020$40.87M–
Q4 FY2019Dec 31, 2019$45.03M–
Q3 FY2019Sep 30, 2019$51.84M–
Q2 FY2019Jun 30, 2019$27.49M–
Q1 FY2019Mar 31, 2019-$16.60M–
Q4 FY2018Dec 31, 2018-$60.50M–
Q3 FY2018Sep 30, 2018-$56.97M–
Q2 FY2018Jun 30, 2018-$44.91M–
Q1 FY2018Mar 31, 2018-$42.03M–
Q4 FY2017Dec 31, 2017-$46.47M–
Q3 FY2017Sep 30, 2017-$56.62M-166.9%
Q2 FY2017Jun 30, 2017-$56.64M–
Q1 FY2017Mar 31, 2017-$72.42M–
Q4 FY2016Dec 31, 2016-$73.46M–
Q3 FY2016Sep 30, 2016$84.62M–

More Coherus Oncology figures

See a number that looks wrong?